Information Provided By: 
Fly News Breaks for September 30, 2015
ESPR
Sep 30, 2015 | 07:40 EDT
JPMorgan analyst Jessica Fye still sees a longer-term upside case in Esperion shares but admits that "patience is needed." The announced phase II study that will evaluate '1002 in combo with high dose statins is important for the company since a lack of data in this setting has been a key part of the bear thesis, Fye tells investors in a research note. She cut her price target for Esperion to $110 from $130 and keeps an Overweight rating on the name. The stock closed yesterday down $16.76 to $18.33.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
